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Humans afflicted with the Wolcott-Rallison syndrome and
mice deficient for PERK (pancreatic endoplasmic reticulum
eIF2 kinase) show severe postnatal growth retardation. In
mice, growth retardation in Perk/ mutants is manifested
within the first few days of neonatal development. Growth
parameters of Perk/ mice, including comparison of body
weight to length and organ weights, are consistent with pro-
portional dwarfism. Tibia growth plates exhibited a reduction
in proliferative and hypertrophic chondrocytes underlying
the longitudinal growth retardation. Neonatal Perk/ defi-
cient mice show a 75% reduction in liver IGF-I mRNA and
serum IGF-I within the first week, whereas the expression of
IGF-I mRNA in most other tissues is normal. Injections of
IGF-I partially reversed the growth retardation of the
Perk/ mice, whereas GH had no effect. Transgenic rescue
of PERK activity in the insulin- secreting -cells of the
Perk/ mice reversed the juvenile but not the neonatal
growth retardation. We provide evidence that circulating
IGF-I is derived from neonatal liver but is independent of GH
at this stage. We propose that PERK is required to regulate the
expression of IGF-I in the liver during the neonatal period,
when IGF-I expression is GH-independent, and that the lack
of this regulation results in severe neonatal growth
retardation. (Endocrinology 144: 3505–3513, 2003)
POSTNATAL GROWTH IN humans and other mammalsis primarily regulated by the concerted action of IGF-I
and GH. Genetic experiments have confirmed the impor-
tance of IGF-I and GH in postnatal growth in mice and have
delineated the developmental periods in which these factors
are individually and jointly required for normal growth (1).
Igf1/ knockout mice are 30–40% smaller than normal at
birth and continue to lag in postnatal growth (2, 3). In con-
trast, mice that are deficient for GH, the GH release factor, or
GH receptor (GHR) grow normally for the first 2 wk before
subsiding to postnatal growth retardation (1, 4–6). Thus,
early neonatal growth in mice appears to be independent of
GH. Later in postnatal development, a primary function of
GH is to induce the expression of IGF-I mRNA in the liver
via the transmembrane GHR and a signaling cascade that
culminates in the transcriptional activation of the Igf-1 gene.
IGF-I, synthesized in the liver, is secreted into the circulatory
system, and most evidence supports the hypothesis that the
liver is the predominant if not sole source of circulating IGF-I
(4, 7, 8). IGF-I is also expressed in many other tissues, in-
cluding the skeletal system, where it may have autocrine
and/or paracrine functions. Unlike the liver, however, IGF-I
expression is completely or partially independent of GH/
GHR in most other tissues (4). Because liver-derived IGF-I
has been argued to be strictly dependent upon GH (4, 9), it
has been assumed that circulating levels of IGF-I are very low
and functionally inconsequential during the first 2 wk of
neonatal growth when longitudinal growth is not dependent
on GH/GHR. Inasmuch as neonatal growth is clearly de-
pendent upon IGF-I, this would imply that neonatal growth
is exclusively dependent on the paracrine/autocrine action
of IGF-I. The importance of circulating IGF-I to longitudinal
growth was also questioned by experiments showing that
mice with a liver-specific knockout of IGF-I (LID) did not
show postnatal growth retardation, although circulating
IGF-I was reduced by approximately 75% at the adult stage
(7, 8). However, this interpretation, which arises from studies
of the LID mice, is contradicted by investigation of the
Ghr/ knockout mice, which exhibit severe postnatal
growth retardation and are completely deficient for circu-
lating IGF-I, but have normal levels of IGF-I expressed in
most other tissues. To explain the unexpected normal growth
in the LID mice, it has been suggested that these mice may
have substantial expression of circulating IGF-I during the
early postnatal development before the Cre-induced deletion
of the Igf-1 gene in the liver has occurred in most of the
hepatocytes (4). The level of circulating IGF-I in the LID or
Ghr/ knockout mice during the neonatal period is un-
known. Moreover, the expression and functional activity of
IGF-I during the neonatal period has not been investigated
in either humans or mice.
Genetic analysis of various mouse strains has revealed that
polygenic variation for IGF-I expression maps to a small
number of loci with major effects on skeletal growth and
development (10). Such loci may correspond to genes that
regulate IGF-I. PERK (pancreatic endoplasmic reticulum
Abbreviations: GHR, GH receptor; HNF, hepatocyte nuclear factor;
LID, liver-specific knockout of IGF-I; PERK, pancreatic endoplasmic
reticulum eIF2 kinase; P21, postnatal d 21; WRS, Wolcott-Rallison
syndrome.
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eIF2 kinase), a type I transmembrane protein kinase span-
ning the endoplasmic reticulum membrane, maps within a
large multigene region on chromosome 6 of mice that bears
one of these loci. Recently, we have generated a knockout
mutation of the mouse Perk gene (11). Loss-of-function mu-
tations in the mouse Perk gene result in three major defects:
postnatal growth retardation, multiple skeletal dysplasias
and osteopenia, and loss of endocrine and exocrine functions
in the pancreas. The same array of defects is seen in the
Wolcott-Rallison syndrome (WRS), a human genetic disease
associated with mutations in the Perk gene (12). Perk/
mice are normal at birth but exhibit an immediate lag in
growth rate during the neonatal period. Inasmuch as this
growth retardation precedes the development of diabetes
and exocrine pancreatic insufficiency by more than 3 wk, we
speculate that the early growth retardation is not caused by
general metabolic defects. Because the early neonatal growth
retardation in Perk/mice is similar than that seen in mice
deficient for IGF-I, we investigated the expression of IGF-I in
Perk/ mice. We show herein that liver IGF-I mRNAs and
serum IGF-I are dramatically reduced in Perk/ mice dur-
ing the neonatal period, whereas the IGF-I receptor and GH
are elevated. Injection of IGF-I, but not GH, reversed the
severe growth retardation of the Perk/ mice, thus sup-
porting the hypothesis that PERK is a major regulator of
IGF-I-dependent neonatal growth. During the course of in-
vestigating the growth retardation of Perk/ mice, we dis-
covered that IGF-I is actively transcribed in the liver during
early neonatal development, resulting in significant levels of
circulating IGF-I before the period when liver IGF-I expres-
sion becomes GH-dependent.
Materials and Methods
Growth plate analysis
All animal experiments were performed in accordance with the rules
and regulations of the Institutional and Animal Care Use Committee.
Tibias from prediabetic mice were isolated and fixed in 10% formalin
overnight, decalcified using Cal-Ex (Fisher Scientific, Pittsburgh, PA) for
3–5 d, embedded in paraffin, cut longitudinally into 5-m midsagittal
sections, and stained with hematoxylin and eosin. Morphometry was
performed on light microscopy photographs of the growth plates cap-
tured at 100 magnification. The total height of the epiphyseal growth
plate was calculated as the distance between the proximal end of the
chondrocyte resting zone to the distal base of the hypertrophic zone.
Proliferative chondrocytes typically appear as flattened discs such that
their height is much smaller than their width. The width of the hyper-
trophic chondrocytes is similar to proliferative chondrocytes, but their
height is proportionally much greater. The boundary between the pro-
liferative zone and hypertrophic zone was defined as the point where
the ratio of cell width to cell height is approximately 2.0, less than 2.0
defined as hypertrophic chondrocytes, and more than 2.0 defined as
proliferative chondrocytes (13). All zone height and cell height mea-
surements were calculated in centimeters on photographs printed at30
and 60 magnification, respectively. Averages from five Perk/ mice
and three Perk/ mice were analyzed, with multiple sections of each
sample calculated. For cell number calculations, at least four columns
per section around the midline were counted by at least three different
coauthors. All measurements were performed on coded photographs to
mask the genotype information from each observer.
RNA extraction and IGF-I mRNA analysis
Long bones (femur and tibia) were isolated from mice after removal
of skin and skeletal muscles. Bone marrow was removed by flushing the
bone cavities with PBS. The bones were cut into small pieces in TRIzol
reagent (Sigma, St. Louis, MO) and homogenized with a Polytron ho-
mogenizer. Liver and pancreas were homogenized in TRIzol reagent
with a sonicator, and the RNA was extracted. DNA contaminating the
RNA sample was digested with RNase-free DNase (Ambion, Inc., Aus-
tin, TX) at 37 C for 60 min. An equal quantity of RNA was primed with
random hexamer primers and was reverse transcribed into cDNA using
M-MLV (Moloney murine leukemia virus) reverse transcriptase (Pro-
mega Corp., Madison, WI). PCR primers for IGF-I amplification are exon
1 forward 5-GAT GGG GAA AAT CAG CAG CC-3, exon 2 forward
5-TGC TGT GTA AAC GAC CCG-3, and common reverse primer
5-CAA CAC TCA TCC ACA ATG CC-3. Primers for tubulin are for-
ward 5-TCC TTC AAC ACC TTC TTC AGT GAG A-3 and reverse
5-GAG GAT GGA ATT GTA GGG CTC AAC-3. IGF-I and tubulin
cDNA was quantified using real-time PCR. Real-time PCRs were carried
out in 1 SYBR Green PCR buffer containing 10 mm Tris-HCl (pH 8.3),
50 mm KCl, 0.8% glycerol, 0.01% Tween 20, 0.25 SYBR Green (Mo-
lecular Probes, Inc., Eugene, OR), and 60 nm ROX I (Synthegen, Houston,
TX). Real-time PCR was performed using the GeneAmp 5700 DNA
amplification system (PE Applied Biosystems, Foster City, CA). The
reaction program included a 94 C denaturation step for 5 min followed
by 35 cycles of 94 C denaturation for 60 sec, 60 C annealing for 60 sec,
and 72 C extension for 60 sec. Detection of fluorescent product was
carried out at the end of the 72 C extension period. PCR products were
subjected to a melting curve analysis and agarose gel electrophoresis.
Data were analyzed and quantified with the GeneAmp 5700 SDS soft-
ware. At a specific threshold in the linear amplification stage, the cycle
differences between amplified tubulin and IGF-I cDNA were used to
determine the relative quantity of IGF-I mRNA.
Calvarial osteoblasts isolation and culture
Calvarial osteoblasts were isolated from mice using a protocol mod-
ified from Ecarot-Charrier et al. (14). Calvaria were removed aseptically
and stripped of the periosteum in culture media (low-glucose DMEM
media with 100 U/ml penicillin and 100 g/ml streptomycin). The
calvaria were cut into small pieces and incubated in the same DMEM
complete media with 10% fetal calf serum at 37 C, 5% CO2 for 1 wk, and
then the bones were removed. Cells were grown for another week until
reaching confluence. Half of the medium was changed with fresh media
every 3 d. For IGF-I secretion, cells were first grown to confluence in the
complete media and then washed and placed in conditioned media in
which the 10% fetal calf serum was substituted with 0.1% BSA. After
24 h, conditioned media and cells were collected separately. Secreted
IGF-I was normalized to total protein in the cell lysates.
IGF-I detection
Serum IGF-I was measured in mice using either enzyme immuno-
assay or RIA-based systems. IGF-I from the serum of neonatal mice and
IGF-I secreted into the conditioned culture media were measured with
an ultrasensitive RIA kit (022-IGF-R21, ALPCO, Windham, NH) with an
assay sensitivity equal to 0.02 ng of IGF-I/ml. This IGF-I assay includes
removal of IGF binding proteins by acid extraction and reducing cross-
reactivity of IGF-II through the addition of a saturating concentration of
exogenous IGF-II. Cross-reactivity to IGF-II is small (0.05%), and the
intraassay coefficient of variation was 0.42%. For adult and juvenile
mice, a rat IGF-I enzyme immunoassay kit (DSL-10-2900, Diagnostic
Systems Laboratories, Webster, TX) was used to detect IGF-I after acid-
ethanol extraction to remove IGF binding proteins. The intraassay and
interassay coefficients of variation were 10 and 12%, respectively.
Results
Perk/ knockout mice exhibit postnatal growth
retardation and a reduction in hypertrophic chondrocytes in
the tibia growth plate
The body weight and size of Perk/ mice is indistin-
guishable from wild-type littermates at birth, but within a
few days they begin to noticeably lag in growth. By the end
of the neonatal period [postnatal d 21 (P21)], male and female
Perk/ mice are on average 50% smaller than normal as a
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consequence of a 4-fold reduction in daily growth rate (Fig.
1). The growth rates of Perk/ males are somewhat more
negatively impacted than females, but this varies among
litters. Examination of the tibia growth plate chondrocytes
(Fig. 2) revealed that Perk/ mice show on average a 22%
reduction in the width of the growth plate, which is largely
due to a 26 and 19% reduction in the width of the hyper-
trophic and proliferative zones, respectively (Table 1). The
width of the resting chondrocyte zone of the Perk/ growth
plate is normal, however. The reduction in the hypertrophic
zone is due to a 28% reduction of the number of cells in the
longitudinal axis (Table 1), consistent with a deficiency in a
primary growth factor. We also noted an abrupt transition
from the proliferative to the hypertrophic zone in the
Perk/ growth plates, as indicated by a deficiency in chon-
drocytes exhibiting intermediate width/height ratios.
Comparison of body length (rump to nose) to total body
weight of Perk/ mice was assessed using the allometric
scaling equation y  axb, where y  body length, x  body
weight, and b is the slope of the regression. A regression
slope near 0.33 is typically found in normal mice as well as
growth-deficient mice that retain allometric proportions (4,
15). The allometric scaling slope of body weight and length
for the Perk/ mice was determined to be 0.32, very close
to previous estimates of wild-type mice as well as Ghr/
and Igf1/ deficient mice. With the exception of the brain,
major organs of Perk/ mice also showed a proportional
reduction in size relative to body weight (Table 2). The
weight of the brain was only marginally reduced in Perk/
mice and constituted 5.36% of the total body weight, com-
pared with 2.75% for wild-type mice. Others have noted that
the brain does not decrease proportionally to total body
weight in Igf-1- and Ghr-deficient mice and speculated that
because the brain grows more rapidly in fetal development
than other organs (16), it is less impacted by postnatal growth
factor deficiencies (4). The spleen in Perk/ mice is some-
what proportionally smaller than expected and shows con-
siderable variation independent of total body size.
Transgenic rescue of PERK expression in the insulin-
secreting -cell defect in Perk/ mice rescues juvenile, but
not neonatal, growth retardation
Perk/ knockout mice continue to display a 3- to 4-fold
reduction in growth rate during the juvenile period (3–6 wk).
Between P22 and P25, these mice develop severe hypergly-
cemia (11), which may negatively impact their growth. To
determine whether the onset of diabetes at the juvenile stage
contributes to the continued growth retardation in Perk/
mice, a Perk transgene targeted to the insulin-secreting-cells
of the islet of Langerhans (denoted PERK) was introduced
into the genome of the Perk/ knockout strain. The result-
ant mice (PERK; Perk/) are deficient in PERK in all tis-
sues except for the insulin-secreting -cells of the endocrine
pancreas. The expression of PERK in the insulin-secreting
-cells of these mice reverses the loss of -cell mass and the
FIG. 2. Tibia growth plates of Perk/ and wild-type (WT) mice.
Representative longitudinal sections of WT and Perk/ proximal
tibia growth plates showing similar resting zones (RZ) and decreased
proliferative zone (PZ) and hypertrophic zone (HZ) in the Perk/
mice. Micrographs are shown at 100 magnification.
TABLE 1. Analysis of tibia growth plate chondrocyte zones in
Perk/ and wild-type (WT) mice
WT Perk/ P
GP (cm) 6.97 (0.14) 5.45 (0.16)  0.0001
RZ (cm) 0.65 (0.05) 0.65 (0.03) ns
PZ (cm) 2.18 (0.10) 1.77 (0.06) 0.0003
HZ (cm) 4.17 (0.13) 3.07 (0.11)  0.0001
HZ cell number 13.12 (0.27) 9.40 (0.25)  0.0001
Values are the mean ( SEM). The heights of the resting (RZ),
proliferative (PZ), and hypertrophic (HZ) zones and the number of
hypertrophic cells were measured as described in Materials and Meth-
ods. WT, n 3; Perk/, n 5. A significant difference between WT
and Perk/ is indicated as a P value (t test). GP, Growth plate; ns,
not significant.
FIG. 1. Growth curves of Perk/ and wild-type mice. Total body
weights of wild-type (WT; open circles and squares), Perk/ (filled
circles and squares with solid line), and PERK; Perk/ (filled
circles and squares with dashed lines) were recorded from birth until
P40. Circles represent female mice and squares represent male mice.
Average sample size: WT males, 33; WT females, 25; Perk/males,
7; Perk/ females, 5; PERK; Perk/ males, 6; and PERK;
Perk/ females, 2.
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development of hyperglycemia (Zhang, P., and D. R.
Cavener, unpublished data). The PERK; Perk/ mice still
exhibit a 4-fold reduction in growth rates during the neonatal
period, indistinguishable from the Perk/ global knockout
strain (Fig. 1). However, at the neonatal-juvenile transition
(P21) these mice exhibit accelerated growth compared with
Perk/ knockout mice. Although PERK; Perk/mice do
not catch up to the wild-type mice in total size, their growth
rates between P20 and P40 are indistinguishable from wild-
type mice.
Perk/ mice are deficient in serum IGF-I and liver
IGF-I mRNA
Genetic analysis of Perk/ mice showed that PERK is
essential for normal growth, particularly during neonatal
development. Comparison of the growth rates of Perk/
mice with various mutations affecting GH, IGF-I, and their
receptors suggested that the Perk/mice might be deficient
in IGF-I because of the early neonatal manifestation of
growth retardation. Analysis of serum IGF-I revealed a dra-
matic reduction in Perk/ mice during neonatal develop-
ment (Fig. 3, top). The severest reduction (25% of normal) was
apparent during the early neonatal period in which IGF-I is
clearly the dominant, if not exclusive, growth factor. In con-
trast, GH serum levels in juvenile mice were somewhat el-
evated (Perk/, 7.07  2.64 ng/ml, vs. wild-type, 4.04 
0.43 ng/ml) as expected due to the reduction in the normal
negative feedback regulation of IGF-I on GH (17–19). In late
neonatal development, the PERK; Perk/ rescued mice
exhibit a deficiency in circulating IGF-I, which is indistin-
guishable from the nonrescued Perk/ knockout mice (Fig.
3, bottom). However, IGF-I levels in thePERK; Perk/mice
recover to normal levels during the second postnatal month,
whereas in contrast, IGF-I levels in Perk/ knockout mice
remain relatively low.
To ascertain the molecular and cellular basis for the re-
duction in IGF-I in the Perk/ mice, the level of the two
major IGF-I mRNA isoforms was determined in liver, be-
cause it is the major source of circulating IGF-I (Fig. 4). Both
IGF-I mRNA isoforms 1 and 2 were substantially reduced in
liver during neonatal development at P5, P7, P10, and P14.
The relative abundance of liver IGF-I mRNA is highly cor-
related with serum IGF-I levels, suggesting that the primary
defect in the IGF-I deficiency in Perk/ mice is caused by
misregulation of the steady state levels of liver IGF-I mRNA.
The expression of IGF-I mRNA was also similarly reduced in
the pancreas of neonatal Perk/ mice (Table 3). However,
in contrast, normal levels of IGF-I mRNA were found in long
bone, kidney, lung, and skeletal muscle of neonatal Perk/
mice (Table 3).
Although the level of IGF-I mRNA in long-bone tissue is
normal, we found that the level of the IGF-I receptor in bone
tissue was elevated (Fig. 5). An increased level of the IGF-I
receptor has been shown in other cases of IGF-I deficiency in
humans (20) and is purported to be due to a relaxation of the
normal negative feedback regulation of IGF-IR by circulating
FIG. 3. Serum IGF-I levels in neonatal, juvenile, and adult mice. Top,
Serum IGF-I levels of neonatal mice from WT (white bars) and
Perk/ (black bars). For each time point, n  3–7 for WT, and n 
2–4 for Perk/. *, P  0.05 based upon a one-tailed t test. Bottom,
Serum IGF-I levels of WT, Perk/, and PERK; Perk/ (hatched
bars) mice (n  3–4). Error bars represent SE values of the mean. *,
P 0.05. **, P 0.01 based on a two-tailed t test comparing Perk/
and PERK; Perk/ mice to wild-type.
TABLE 2. Comparison of organ weights between wild-type (WT) and Perk/ mice
Weight ( SEM) % Body weight
WT KO WT KO KO/WT (%)
Body weight (g) 15.4  0.8 7.5  0.7
Brain (mg) 438.2  8.5 356.3  15.6 2.75 5.36 195.0
Heart (mg) 109.0  9.3 51.8  6.9 0.67 0.74 110.4
Lungs (mg) 141.4  2.7 84.8  5.3 0.89 1.27 143.2
Liver (mg) 722.1  65.1 368.6  108.2 4.42 4.89 110.6
Spleen (mg) 97.2  5.8 40.6  11.1 0.64 0.50 78.4
Kidneys (mg) 210.5  15.0 120.6  19.2 1.37 1.55 113.3
Pancreas (mg) 95.6  8.1 43.7  11.0 0.59 0.59 99.6
Values are weight averages ( SEM) of five to nine animals and relative (percentage of body weight) values. The last column shows percentage
values of Perk/ organ weight relative to wild-type. KO, Knockout.
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IGF-I. To further assess potential defects in IGF-I expression
in bone tissue, IGF-I expression and secretion were assayed
in primary cultures of calvarial osteoblasts isolated from
Perk/mice. Calvarial osteoblasts of Perk/mice exhibit
normal levels of IGF-I mRNAs and secrete normal amounts
of mature IGF-I (Fig. 6). Together, these results suggest that
the neonatal growth retardation is not due to an autocrine/
paracrine IGF-I deficiency in bone or other tissues, but rather
due to a reduction of circulating IGF-I secreted from the liver.
However, we have not been able to quantitatively assess the
level of IGF-I expression specifically within the growth plate
chondrocytes, and therefore we cannot rule out a possible
reduction in locally expressed IGF-I in the growth plate that
may negatively impact longitudinal growth of long bones.
Beyond the neonatal period, the expression of IGF-I
mRNA is largely controlled by GH as mediated by the GHR
(2, 4). To ascertain whether the deficiency of liver IGF-I in the
Perk/mice was caused by a deficiency of GHR, as seen in
the Laron syndrome (22), GHR mRNA was quantitatively
measured in the liver by real-time RT-PCR and normalized
to tubulin mRNA. GHR mRNA was detected in the livers of
P14 Perk/ mice and was not substantially different from
that seen in wild-type littermates [GHR mRNA Perk/,
0.17  0.008 (n  3); wild-type, 0.26  0.026 (n  3)].
Injection of IGF-I reverses the severe growth retardation of
the Perk/ mice.
We reasoned that if the deficiency in circulating IGF-I in
the Perk/ mice is the cause of the neonatal growth retar-
dation, injection of IGF-I would lead to a reversal of the
growth retardation. Perk/ neonatal mice were injected sc
twice daily with 125 ng IGF-I/g total body weight during the
entire neonatal period (P2–P21). Within a few days after the
onset of IGF-I injection, the injected Perk/ mice began to
FIG. 4. Relative abundance of IGF-I transcripts in livers of neonatal
Perk/ and wild-type (WT) mice. WT (white bars) and Perk/
(black bars) levels of IGF-I transcripts initiated from exon 1 and exon
2. For each group, n 3–4. Error bars represent SE values of the mean.
FIG. 5. Expression of IGF-I receptor- in bone tissue. IGF-IR ( sub-
unit) level of WT (/) and Perk/ tibia and thoracic vertebrae.
Ten micrograms of total protein were loaded in each lane. -Actin was
used for a loading control.
FIG. 6. Expression of IGF-I mRNA and secretion of IGF-I in primary
cultured osteoblasts. Top, Relative abundance of IGF-I mRNA in
cultured osteoblasts from P7 and P17 WT (white bars) and Perk/
mice (black bars). Bottom, Levels of IGF-I secreted into culture media.
For WT, n  7; for Perk/, n  5. Error bars represent SE values
of the mean.
TABLE 3. Igf-1 mRNA expression in major organs and tissues of
neonatal wild-type (WT) and Perk/ mice
Organ/tissue WT Perk/ WT vs. Perk/
Pancreas 100 (100)  10.9 49  11.5 P  0.011
Bone 100 (10)  15.8 110  18.3 ns
Kidney 100 (27)  35.5 103  7.4 ns
Lung 100 (21)  14.8 116  12.7 ns
Muscle 100 (24)  8.3 125  36.2 ns
Values are the mean ( SEM) of three to six animals, normalized to
WT. Values in parentheses are WT Igf-1 averages for each organ
normalized to Igf-1 levels in the pancreas to provide relative com-
parison among organs. A significant difference is indicated by a P
value (t test).
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exhibit an accelerated growth rate compared with nonin-
jected Perk/ mice (Fig. 7). Averaged over the neonatal
developmental period, the IGF-I injected Perk/ mice ex-
hibited a 2-fold higher daily growth rate than noninjected
mutant mice. In contrast, twice-daily injection of GH (3 g/g
body weight) during the late neonatal and juvenile state
(P15–P42) had no effect on the growth rate of the Perk/
mice (data not shown).
Serum titers of IGF-I and body weight are highly correlated
during neonatal but not juvenile development
IGF-I levels are modulated by a number of environmental
and genetic factors, and normal variation of IGF-I may im-
pact postnatal growth. Considerable variation in IGF-I levels
was seen for Perk mutant and wild-type mice. During neo-
natal and juvenile development, body weight generally re-
flects relative growth rates. We determined the correlation of
body weight and IGF-I titers at the neonatal (0–3 wk) and
juvenile (3–6 wk) stages for Perk/ and wild-type mice
(Fig. 8). During the neonatal period, a highly significant
correlation (r 0.93) was observed between body weight and
IGF-I titers; this strong positive correlation was observed for
both wild-type (r  0.94) and Perk/ (r  0.80) mice when
analyzed separately as well. In contrast, no significant cor-
relation was observed during the juvenile stage for either
wild-type mice or Perk/mice. These findings suggest that
IGF-I levels present in both normal and Perk/ mice are
limiting for neonatal growth but permissive for juvenile
growth.
Discussion
According to the somatomedin hypothesis of postnatal
growth, GH mediates skeletal growth by activating the ex-
pression of IGF-I in the liver and secretion into the circulation
(17, 18). GH has been shown to regulate the transcription of
IGF-I in the liver via signaling through the GHR and down-
stream effectors such as STAT5b (signal transducer and ac-
tivator of transcription 5b) and hepatocyte nuclear factor
(HNF)1. During the first 2 wk of neonatal development,
however, GHR appears to have no effect on growth (4).
Knockout mutations of Igf1 in mice, however, show that the
lack of IGF-I leads to perinatal growth retardation (2, 3, 23),
and by P14 Igf1/mice are only half the size of normal. An
unresolved issue is the source and regulation of IGF-I during
the neonatal period when IGF-I expression is independent of
GH. In addition to the liver, IGF-I has been shown to be
expressed in a variety of tissues, and in many of these other
tissues IGF-I expression is apparently independent of GH (4,
9). Thus, others have speculated that neonatal growth may
be under paracrine and/or autocrine control of IGF-I inde-
pendently of GH (7, 8). The potential contribution of liver-
derived serum IGF-I to early neonatal growth has been
largely ignored due to the prevalent view that IGF-I expres-
sion in the liver is strictly GH-dependent. However, the
notion that IGF-I expression in the liver is strictly GH-
dependent is based on studies of juvenile and mature adult
mice. Genetic ablation of IGF-I in the mouse liver as achieved
in the LID mice using the Cre/loxP system reduced serum
FIG. 7. Growth curves of Perk/ and WT mice injected with IGF-I.
Body weights were recorded from mice with and without IGF-I in-
jection (125 ng/g body weight, sc injections, twice daily) from P2 to
P21. On average, n  22 for noninjected WT, n  3 for noninjected
Perk/, n  6 for IGF-I-injected WT, and n  3 for IGF-I-injected
Perk/. Error bars represent SE values of the mean.
FIG. 8. Correlation of body weight to serum IGF-I in Perk/ and
WT mice. Top, Correlation of body weight to serum IGF-I in Perk/
(black squares) and WT (white circles) neonatal mice ranging from age
P5–P14. Correlation coefficient (r) for Perk/mice is 0.80, whereas
the correlation coefficient for WT mice is 0.94. Bottom, Correlation of
body weight to serum IGF-I in Perk/ and WT juvenile mice rang-
ing in age from P23–P42.
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IGF-I by 75%, but surprisingly had no impact on postnatal
growth (7, 8). However, the ablation of IGF-I in these exper-
iments either was not induced or likely did not occur in the
liver of the LID mice until after the early neonatal period and
therefore would not have significantly reduced the expres-
sion of IGF-I during neonatal development. We show herein
that a significant level of IGF-I mRNA is expressed in the
liver of 5- to 7-d-old mice as well as a significant level of IGF-I
in the serum. Moreover, Rotwein and colleagues (24, 25) have
reported significant IGF-I mRNA in the liver in neonatal rats
(p7), which they argue is GH independent. In the absence of
a functional PERK eIF2 kinase gene, both liver IGF-I mRNA
and serum IGF-I are dramatically reduced in neonatal mice,
whereas the IGF-I mRNA is normally expressed in most
other tissues including bone. However, the tibia growth
plates in neonatal Perk/ mice showed a reduction in the
proliferative and hypertrophic zone consistent with the lon-
gitudinal growth defect. Injection of IGF-I, but not GH, par-
tially reverses the neonatal growth retardation of the
Perk/ mice. Together, these data support the hypothesis
that liver-derived IGF-I, whose expression is PERK depen-
dent but independent of GH, plays a major role in neonatal
longitudinal growth. Our data do not exclude the possibility
that IGF-I also plays a paracrine/autocrine role of IGF-I
during neonatal growth; however, our finding that IGF-I is
normally expressed in major organs and tissues in Perk/
mice, with the exception of the liver and pancreas, suggests
that the endocrine role of IGF-I dominates longitudinal
growth during the neonatal period.
We showed that although a 2-fold reduction in circulating
IGF-I during the neonatal period negatively impacts growth,
it does not retard growth during the juvenile stage. This
finding is consistent with genetic ablation experiments of the
Igf-1 gene, which show that global and early ablation of IGF-I
dramatically impacts growth, whereas a reduction of circu-
lating IGF-I during the juvenile period has no significant
impact on growth (2, 3, 7, 8, 23). In addition, we showed that
serum IGF-I and body weights are highly correlated during
neonatal development, but showed no correlation during
juvenile development. Variation in circulating IGF-I among
human infants has also been shown to be significantly cor-
related with growth and the age at which the childhood
growth stage is reached (26). The correlation between IGF-I
and growth is apparent in infants before the stage at which
the effect of GH on linear growth becomes prominent. Sim-
ilar to mice, IGF-I continues to rise in humans beyond the
neonatal/childhood stage, but growth rates are no longer
correlated with normal variation in IGF-I levels. We propose
that circulating IGF-I is the major limiting factor for neonatal
growth but may only limit juvenile growth if its levels are
exceedingly low (10% of normal). Thus, IGF-I is permissive
for juvenile growth over a broad range.
Yakar et al. (27) have drawn a similar conclusion regarding
the importance of a threshold of circulating IGF-I during the
juvenile and adult stages. They showed that mice lacking
liver-specific expression of IGF-I (LID) and mice globally
deficient for the ALS (acid labile subunit) each exhibit a
substantial reduction in circulating IGF-I (25 and 35% nor-
mal, respectively), but neither exhibited a substantial reduc-
tion in postnatal growth rates. However, the double mutant
combination LID/ALSKO (LID/acid labile subunit knock-
out) exhibits a further reduction of circulating IGF-I (10–15%
normal) and showed a substantial reduction in postnatal
growth rates. Quantitative variation in circulating IGF-I
above a minimal threshold at juvenile and adult stages thus
appears to have a negligible impact on longitudinal growth;
however, variation in IGF-I associated with different mouse
strains has been shown to strongly influence bone density
and skeletal morphology (10, 28, 29). Moreover, the LID
mouse exhibits diminished bone density suggesting that the
level of circulating IGF-I derived from the liver has a pro-
nounced effect on bone architecture, although longitudinal
growth is normal in these mice. Thus, we conclude that the
endocrine function of IGF-I is rate limiting for longitudinal
growth during the neonatal period, whereas it is only lim-
iting for bone density and bone modeling during the juvenile
and adult stages.
Humans afflicted with the WRS, caused by a loss-of-func-
tion mutation in the Perk gene, typically develop diabetes
within the first 2 months, similar to Perk/ mice. IGF-I
deficiency has been reported in one WRS patient (30), but
apparently has not been examined in most WRS patients.
Because humans do not exhibit as rapid longitudinal growth
during the first postnatal month as seen in mice, it has not
been possible to determine whether the growth retardation
apparent in the first 2 yr in WRS is due to a primary defect
in IGF-I or due to an indirect effect of the severe hypergly-
cemia. For Perk/mice, however, we show that a dramatic
reduction in neonatal growth precedes the development of
hyperglycemia, which does not occur until the early juvenile
stage (11). Thus, the neonatal growth retardation is not
caused by diabetes. We speculate that growth retardation
manifested in the WRS during the neonatal period is also
caused by a deficiency of IGF-I and may therefore respond
to neonatal IGF-I therapy.
In contrast, we have shown that rescuing PERK expression
in the insulin-secreting -cells of the Perk/ mice reverses
the juvenile growth retardation thus implicating hypergly-
cemia as the cause of growth retardation in the Perk/
knockout mice during this later postnatal stage. Hypergly-
cemia is known to precipitate a reduction in circulating IGF-I,
and the longitudinal growth of some individuals suffering
from other forms of early onset juvenile diabetes may be
delayed (31, 32). The -cell rescued Perk/ mice (PERK;
Perk/) recover normal titers of IGF-I during the juvenile
period, suggesting that hyperglycemia may be repressing the
expression of IGF-I in the Perk/mice once hyperglycemia
is manifested in the early juvenile state (P22–P24). Although
the increase in IGF-I titers in the PERK; Perk/ rescued
mice is correlated with an increase in growth rates compared
with the global Perk/ mice, we suggest the increase in
IGF-I may not be responsible for increasing growth rates
based upon studies of conditional knockouts of IGF-I in the
liver (LID). The LID mice exhibit IGF-I levels that are com-
parable to the Perk/mice in 1-month-old mice, yet do not
exhibit growth retardation, suggesting that the reduced level
of IGF-I does not limit growth at this stage. Hyperglycemia
affects a number of other metabolic processes that directly
impact growth, including repression of the GLUT4 trans-
porter and the IGF-I receptor in humeral growth plates (33).
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We postulate that the growth retardation seen in the Perk/
mutants, specifically during the juvenile period, may be
caused by such hyperglycemic effects.
Liver dysfunctions are known to reduce the expression of
IGF-I resulting in postnatal growth retardation (34, 35). How-
ever, Perk/mice appear to express normal levels of liver-
enriched genes including albumin, apolipoprotein E, apoli-
poprotein CI, and serum AST (aspartate aminotransferase)
levels (data not shown). In addition, histological examination
of the liver of Perk/ mice appears normal. We conclude
that the down-regulation of IGF-I in the liver of Perk/mice
has a specific effect on the transcription and/or stability of
the IGF-I mRNAs and is not due to a general liver dysfunc-
tion. The mechanism underlying the regulation of IGF-I in
the liver during the neonatal period by PERK is unknown.
We have examined the expression of the key transcriptional
regulatory factors that are purported to regulate IGF-I ex-
pression in the liver, including HNF1, HNF3, HNF4,
CAAT enhancer binding protein (C/EBP), and C/EBP,
but we did not detect any significant differences in their
expression in the liver of Perk/ mice (Li, Y., and D. R.
Cavener, unpublished data). However, these factors may
only be required for GH-dependent regulation of IGF-I later
in development. Regulatory factors that specifically control
GH-independent expression of liver IGF-I during the neo-
natal period have been speculated to exist in rats (24, 25) but
have not yet been identified.
The translation initiation factor eIF2 is the prime, if not
exclusive, substrate of PERK. Phosphorylation of eIF2
(Ser51) may have two diametrically opposed effects on trans-
lation initiation, repression or activation, depending on the
specific mRNA and the degree to which the eIF2 is phos-
phorylated. Hyperphosphorylation, particularly under
stress conditions, may lead to the repression of global protein
synthesis, whereas more modest levels of eIF2 phosphor-
ylation under normal developmental and physiological
states can have a very different effect, namely the activation
of translation of specific genes, particularly those encoding
regulatory functions (36, 37). We speculate that PERK may be
required in the liver to regulate the translation initiation of
one or more regulatory factors that control neonatal expres-
sion of IGF-I mRNA. Although some of these factors that
control the neonatal expression of IGF-I in the liver may be
identical to those required for juvenile and adult regulation
of IGF-I, we propose that one or more neonatal-specific fac-
tors are required for IGF-I expression and are under the
control of PERK.
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